|1.||Kindler, H L: 1 article (08/2001)|
|2.||Eng, C: 1 article (08/2001)|
|3.||Schilsky, R L: 1 article (08/2001)|
|4.||Eager, R: 1 article (10/2000)|
|5.||Tkaczuk, K: 1 article (10/2000)|
|6.||Pazdur, R: 1 article (10/2000)|
|7.||Thompson, J: 1 article (10/2000)|
|8.||Sekar, K: 1 article (10/2000)|
|9.||Nemunaitis, J: 1 article (10/2000)|
|10.||Hoff, P M: 1 article (10/2000)|
|1.||Stomach Neoplasms (Stomach Cancer)
08/01/1994 - "The combination therapy of BOF-A2 with CDDP was effective against stomach cancer (H-111) from the cellular change and decreased side effect. "
01/01/2000 - "Based on the above findings, BOF-A2 is considered to be a promising anticancer drug for patients with advanced gastric cancer."
08/01/1994 - "The combination therapy of BOF-A2 with MMC showed additive effect against stomach cancer (H-111) from IR and cellular changes. "
01/01/2000 - "The antineoplastic effects of BOF-A2 (Emitefur), a 5-fluorouracil (5-FU) derivative, in capsule form were assessed in patients with advanced gastric cancer, in a multicenter late phase II study and at 11 different hospitals. "
01/01/2000 - "A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/1994 - "Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. "
01/01/1994 - "Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation, was administered to 71 non-small cell lung cancer (NSCLC) patients in a multi-center phase II study. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
07/01/1994 - "We investigated the effects of BOF-A2 on the metastasis of colorectal cancer using artificial (experimental) and spontaneous metastasis of Colon 26 tumor cells. "
08/01/2001 - "The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer."
10/01/2000 - "To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors. "
10/01/2000 - "Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors."
08/01/1994 - "BOF-A2 was expected to be a promising new anti-cancer agent in the future clinical trial."
02/01/1993 - "Antitumor effects of BOF-A2 given intermittently was evaluated with human gastric (H-111, H-83), colorectal (H-110, H-143) and lung (H-74, LC-376) cancers xenografted in nude mice and compared with those by continuous administration. "
09/01/1990 - "Twenty-five consecutive oral administration of BOF-A2 at 17.5 to 30 mg/kg over 4 weeks caused marked inhibition or regression (over 92% of inhibition rate) to the growth of H-81, H-143 and H-31 cancers. "
02/01/1989 - "The ED50 (the dose for 50% inhibition) values of BOF-A2 were 25 mg/kg against sarcoma-180 and 15 mg/kg against Yoshida sarcoma. "
02/01/1989 - "The antitumor activity of BOF-A2 was investigated in sarcoma-180-bearing mice and Yoshida sarcoma-bearing rats. "
07/01/1987 - "BOF-A1 and BOF-A2, new compounds combined with CNDP were markedly active against mouse sarcoma 180 and rat Yoshida sarcoma."
02/01/1989 - "After oral administration of BOF-A2 at 15 mg/kg to Yoshida sarcoma-bearing rats, BOF-A2 was hydrolyzed to EM-FU, CNDP and 5-FU, and their maximum concentrations in the blood were 2000 ng/ml, 300 ng/ml and 40 ng/ml, respectively. "
|5.||Leucovorin (Folinic Acid)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Drug Therapy (Chemotherapy)